ESSA Pharma (NASDAQ:EPIX) Stock Price Passes Above 50 Day Moving Average of $5.44

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.44 and traded as high as $6.85. ESSA Pharma shares last traded at $6.05, with a volume of 181,690 shares.

ESSA Pharma Price Performance

The firm’s fifty day moving average price is $5.48 and its 200-day moving average price is $6.29. The company has a market capitalization of $286.58 million, a price-to-earnings ratio of -10.25 and a beta of 1.84.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.10. On average, research analysts predict that ESSA Pharma Inc. will post -0.71 earnings per share for the current year.

Institutional Trading of ESSA Pharma

Several institutional investors have recently modified their holdings of the business. RTW Investments LP bought a new stake in shares of ESSA Pharma in the fourth quarter worth $15,171,000. Janus Henderson Group PLC boosted its position in ESSA Pharma by 7.9% during the first quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock valued at $9,978,000 after acquiring an additional 85,760 shares during the last quarter. BNP Paribas Financial Markets boosted its position in ESSA Pharma by 164.9% during the fourth quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock valued at $379,000 after acquiring an additional 35,771 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in ESSA Pharma during the first quarter valued at $38,000. Institutional investors own 75.12% of the company’s stock.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.